[NEWSMP] 7 stocks up double digits in Medical Supplies index...47 constituents combined market capitalization returned to 130 trillion level
The combined market capitalization of the 47 constituents of the Medical Supplies index has recovered to the 130 trillion won level.
According to the Korea Exchange, the stock prices of 32 of the 47 constituents of the Medical Supplies index rose for the month of March, while the other 15 fell.
Among the 32 constituents which stock prices rose, Shinpoong Pharm's stock surged 29.3%, while Samil Pharmaceutical and Kukje Pharm's stock soared 28.8% and 27.2%, respectively, up nearly 30%.
A total of 7 constituents posted double-digit gains, including Pharmicell 15.7%, Yuhan Corp 13.8%, Aprogen Biologics 12.4%, and Myungmoon Pharm 11.1%.
Shares of Boryung, Hanall Biopharma, Samsung Biologics, Celltrion, Yuyu Pharma, Daewoong Pharmaceutical, Yungjin Pharmaceutical, and Dongsung Pharmaceutical also rose more than 5%.
In addition, the stock prices of Chongkundang Bio, Handok, Orient Bio, GC Biopharma, Reyon Pharmaceutical, Whanin Pharm, Chongkundang, Bukwang Pharmaceutical, Hyundai Pharmaceutical, Chongkundang Holdings, Ilyang Pharmaceutical, Jeil Pharmaceutical, Hana Pharm, Daewon Pharmaceutical, Ildong Pharmaceutical, Kyongbo Pharmaceutical, and Kwangdong Pharmaceutical also up from the end of February.
On the other hand, Samsung Pharm's stock price fell 14.7%, the only double-digit decline among the 47 constituents of the Medical Supplies index, and Daewoong and Ilsung Pharmaceuticals also fell more than 5%.
Additionally, the stock prices of Bionote, Dongwha Pharm, JW Life Science, Pharmgen Science, Samjin Pharmaceutical, Dong-A ST, JW Pharmaceutical, GenOne Life Science, Korea United Pharm, Hanmi Pharmaceutical, Ildong Holdings, and SK Bioscience also fell from the end of February.
As the stock prices of 32 companies, or two-thirds of the 47 constituents of the Medical Supplies index, rose, the combined market capitalization of the index rose by 7.912 trillion won, from 126.4775 trillion won to 134.3898 trillion won, returning to the 130 trillion won level.
Samsung Biologics, which has the largest market capitalization among the Medical Supplies index constituents, increased by 4.569 trillion won over the month, while Celltrion's market capitalization also increased by 2.5076 trillion won, returning to the 40 trillion won level.
In addition, Yuhan Corp increased by 745.9 billion won to 6 trillion won level, Shinpoong Pharm and Hanall Biopharma also increased by more than 100 billion won.
Daewoong, on the other hand, was the only company among the 47 constituents of the Medical Supplies index which market capitalization shrank by more than 100 billion won.
As of March 29, Samsung Biologics had the largest market capitalization with 59.1456 trillion won, followed by Celltrion with 41.6911 trillion won.
The market capitalization of Yuhan Corp was 6.1520 trillion won, further widening the gap with SK Bioscience(4.7095 trillion won) and Hanmi Pharmaceutical(4.2661 trillion won).
Meanwhile, the market capitalization of Hanall Biopharma was close to 2 trillion won level with 1.9538 trillion won, while Chongkundang, GC Biopharma, Daewoong Pharmaceutical, Daewoong maintained the 1 trillion won level.
